| Product Code: ETC7644892 | Publication Date: Sep 2024 | Updated Date: Apr 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Israel continued to import angiogenesis inhibitors and simulators from top exporting countries such as Switzerland, UK, Belgium, USA, and Germany. The market concentration, as measured by the Herfindahl-Hirschman Index (HHI), remained low, indicating a competitive landscape. The compound annual growth rate (CAGR) for the period 2020-2024 was negative at -2.14%, with a slight improvement in the growth rate from 2023 to 2024 at -0.41%. This data suggests a stable market with diverse sources of imports for angiogenesis inhibitors and simulators in Israel.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Angiogenesis Inhibitor and Simulator Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Angiogenesis Inhibitor and Simulator Market Revenues & Volume, 2022 & 2032F |
3.3 Israel Angiogenesis Inhibitor and Simulator Market - Industry Life Cycle |
3.4 Israel Angiogenesis Inhibitor and Simulator Market - Porter's Five Forces |
3.5 Israel Angiogenesis Inhibitor and Simulator Market Revenues & Volume Share, By Product Type, 2022 & 2032F |
3.6 Israel Angiogenesis Inhibitor and Simulator Market Revenues & Volume Share, By End User, 2022 & 2032F |
4 Israel Angiogenesis Inhibitor and Simulator Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer and other diseases requiring angiogenesis inhibitors and stimulators |
4.2.2 Rising investments in research and development of novel angiogenesis inhibitors and stimulators |
4.2.3 Growing adoption of targeted therapies for cancer treatment in Israel |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of angiogenesis inhibitors and stimulators |
4.3.2 High cost associated with the development and commercialization of these therapies |
5 Israel Angiogenesis Inhibitor and Simulator Market Trends |
6 Israel Angiogenesis Inhibitor and Simulator Market, By Types |
6.1 Israel Angiogenesis Inhibitor and Simulator Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 Israel Angiogenesis Inhibitor and Simulator Market Revenues & Volume, By Product Type, 2022 - 2032F |
6.1.3 Israel Angiogenesis Inhibitor and Simulator Market Revenues & Volume, By Intussusceptive Angiogenesis, 2022 - 2032F |
6.1.4 Israel Angiogenesis Inhibitor and Simulator Market Revenues & Volume, By Sprouting Angiogenesis, 2022 - 2032F |
6.2 Israel Angiogenesis Inhibitor and Simulator Market, By End User |
6.2.1 Overview and Analysis |
6.2.2 Israel Angiogenesis Inhibitor and Simulator Market Revenues & Volume, By Hospitals, 2022 - 2032F |
6.2.3 Israel Angiogenesis Inhibitor and Simulator Market Revenues & Volume, By Clinics, 2022 - 2032F |
6.2.4 Israel Angiogenesis Inhibitor and Simulator Market Revenues & Volume, By Others, 2022 - 2032F |
7 Israel Angiogenesis Inhibitor and Simulator Market Import-Export Trade Statistics |
7.1 Israel Angiogenesis Inhibitor and Simulator Market Export to Major Countries |
7.2 Israel Angiogenesis Inhibitor and Simulator Market Imports from Major Countries |
8 Israel Angiogenesis Inhibitor and Simulator Market Key Performance Indicators |
8.1 Number of clinical trials involving angiogenesis inhibitors and stimulators in Israel |
8.2 Research and development expenditure on angiogenesis inhibitor and simulator technologies |
8.3 Number of partnerships and collaborations between pharmaceutical companies for developing angiogenesis inhibitors and stimulators. |
9 Israel Angiogenesis Inhibitor and Simulator Market - Opportunity Assessment |
9.1 Israel Angiogenesis Inhibitor and Simulator Market Opportunity Assessment, By Product Type, 2022 & 2032F |
9.2 Israel Angiogenesis Inhibitor and Simulator Market Opportunity Assessment, By End User, 2022 & 2032F |
10 Israel Angiogenesis Inhibitor and Simulator Market - Competitive Landscape |
10.1 Israel Angiogenesis Inhibitor and Simulator Market Revenue Share, By Companies, 2025 |
10.2 Israel Angiogenesis Inhibitor and Simulator Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here